Population pharmacokinetics of pegaptanib in patients with neovascular, age-related macular degeneration

Journal of Clinical Pharmacology

Volumn 52, Issue 8, 2012, Pages 1186-1199

  Basile, Anthony S ^a   Hutmacher, Matt ^b   Nickens, Dana ^a   Nielsen, Jace ^b   Kowalski, Ken ^b   Whitfield, Lloyd ^c   Masayo, Oishi ^d   Nakane, Masami ^d  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b ANN ARBOR PHARMACOMETRICS GROUP   (United States)

^c LW Solutions LLC   (United States)

^d PFIZER INC   (United States)

Author keywords

age related macular degeneration; clearance; Pegaptanib; population pharmacokinetics; renal function

Indexed keywords

CREATININE; PEGAPTANIB;

AGE; AGED; AREA UNDER THE CURVE; ARTICLE; ASIAN AMERICAN; BODY WEIGHT; COMPARTMENT MODEL; CREATININE CLEARANCE; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXPOSURE; EUROPEAN AMERICAN; FEMALE; HUMAN; JAPANESE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

AGED; APTAMERS, NUCLEOTIDE; AREA UNDER CURVE; COHORT STUDIES; FEMALE; HUMANS; KIDNEY FUNCTION TESTS; MACULAR DEGENERATION; MALE; RENAL INSUFFICIENCY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84864403826     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011412961     Document Type: Article

References (27)

1. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age- related macular degeneration. Am J Ophthalmol.. 2004 ; 137: 486-495 (Pubitemid 38328641)
2. Bressler NM. Age related macular degeneration is the leading cause of blindness. JAMA. 2004 ; 291: 1900-1901 (Pubitemid 38509505)
3. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004 ; 122: 564-572 (Pubitemid 38456293)
4. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. Surv Ophthalmol. 1995 ; 39: 367-374
5. Blau HM, Banfi A. The well-tempered vessel. Nat Med. 2001 ; 7: 532-534 (Pubitemid 32448310)
6. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000 ; 407: 249-257
7. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem. 1995 ; 270: 13333-13340
8. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular specific growth factors and blood vessel formation. Nature. 2000 ; 407: 242-248
9. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol. 1997 ; 81: 154-162 (Pubitemid 27092496)
10. Keck PJ, Hauser SD, Krivi G, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989 ; 246: 1309-1312 (Pubitemid 20066717)
11. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol. 2001 ; 280: C1358-1366
12. Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol. 2009 ; 20: 158-165
13. Ng EW, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006 ; 5: 123-132
14. Nimjee SM, Rusconi CP, Sullenger BA. Aptamers: an emerging class of therapeutics. Annu Rev Med. 2005 ; 56: 555-583 (Pubitemid 40299797)
15. Drolet DW, Nelson J, Tucker CE, et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res.. 2000 ; 17: 1503-1510 (Pubitemid 32217559)
16. Reyderman L, Stavchansky S. Pharmacokinetics and biodistribution of a nucleotide-based thrombin inhibitor in rats. Pharm Res. 1998 ; 15: 904-910 (Pubitemid 28307833)
17. Geary RS. Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2009 ; 5: 381-391
18. Tucker CE, Chen LS, Judkins MB, Farmer JA, Gill SC, Drolet DW. Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. J Chromatogr B Biomed Sci Appl. 1999 ; 732: 203-212 (Pubitemid 29421761)
19. Healy JM, Lewis SD, Kurz M, et al. Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm Res. 2004 ; 21: 2234-2246 (Pubitemid 40568437)
20. Beal SL, Sheiner LB, Boeckmann A, Bauer RJ NONMEM User's Guides (1989-2009). Ellicott City, Md: Icon Development Solutions ; 2009:
21. S-Plus for Windows. Seattle, Wash: Data Analysis Division, MathSoft ; 2005:
22. Stratford RE, Carson LW, Dodda-Kashi S, Lee VH. Systemic absorption of ocularly administered enkephalinamide and inulin in the albino rabbit: extent, pathways, and vehicle effects. J Pharm Sci. 1988 ; 77: 838-842 (Pubitemid 19028871)
23. Ahn JE, Karlsson MO, Dunne A, Ludden TM. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 2008 ; 35: 401-421
24. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001 ; 28: 481-504 (Pubitemid 33151426)
25. Kowalski KG, Hutmacher MM. Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test. J Pharmacokinet Pharmacodyn. 2001 ; 28: 253-276
26. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976 ; 16: 31-34
27. Winters ME Basic Clinical Pharmacokinetics. Vancouver, Wash: Applied Therapeutics ; 1994: